Correlation between lncRNA AC079767.4 variants and liver injury from antituberculosis treatment in West China

Zhao, Zhenzhen; Peng, Wu; Wu, Lijuan; Ying, Binwu

doi:10.1016/j.jiac.2019.07.003

Cited by 4 publications

(5 citation statements)

References 20 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 Previous studies had confirmed that a variety of lncRNA gene variants were associated with the genetic risk of PTB, moreover, the expression of NEAT1 in PTB patients was abnormal. 14 , 15 To further analyze the role of NEAT1 gene variation in the pathogenesis of PTB, we explored the role of NEAT1 gene rs2239895, rs3741384, rs3825071, rs512715 variants in PTB. However, no significant result was found.…”

Section: Discussionmentioning

confidence: 99%

“… 12 , 13 In addition, the single nucleotide polymorphisms (SNP) in lncRNA genes have been shown to influence the susceptibility and clinical presentation of PTB. 14–16 The data of Zhao et al indicated that lncRNA AC079767.4 polymorphism had the potential to serve as a novel biomarker for PTB diagnosis. 14 …”

Section: Introductionmentioning

confidence: 99%

“… 14–16 The data of Zhao et al indicated that lncRNA AC079767.4 polymorphism had the potential to serve as a novel biomarker for PTB diagnosis. 14 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association Between Genetic Polymorphisms of lncRNA NEAT1 and Pulmonary Tuberculosis Risk, Clinical Manifestations in a Chinese Population

Li¹,

Wang²,

Tang³

et al. 2022

IDR

View full text Add to dashboard Cite

Background Recent studies have shown that abnormal expression of lncRNA NEAT1 is associated with the progression of pulmonary tuberculosis (PTB). The aim of our study was to analyze the relationship between single nucleotide polymorphisms (SNPs) of NEAT1 gene and susceptibility to PTB. Methods Four SNPs (rs2239895, rs3741384, rs3825071, rs512715) in NEAT1 gene were genotyped in 479 patients with PTB and 476 controls by improved multiple ligase detection reaction (iMLDR) in a Chinese population. Results We found no significant differences in allele and genotype frequencies of NEAT1 gene rs2239895, rs3741384, rs3825071, rs512715 between PTB patients and controls (all P > 0.05). There was no statistically significant association between genotype frequency distribution of dominant model, as well as recessive model, and genetic susceptibility to PTB patients (all P > 0.05). The TT genotype, T allele frequencies of rs3825071 were significantly increased in sputum smear-positive PTB patients when compared to sputum smear-negative PTB patients ( P = 0.010, P = 0.003, respectively). Haplotype analysis shown that NEAT1 haplotype frequency was not associated with PTB susceptibility. Conclusion NEAT1 gene polymorphisms were not associated with the risk of PTB in Chinese population, and rs3825071 polymorphism might be related to sputum smear-positive in PTB patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association Between Genetic Polymorphisms of lncRNA NEAT1 and Pulmonary Tuberculosis Risk, Clinical Manifestations in a Chinese Population

Li¹,

Wang²,

Tang³

et al. 2022

IDR

View full text Add to dashboard Cite

show abstract

“…Regarding treatment failure/recurrence, the lncRNA ( LINC01875 rs1055229) T allele, with a MAF of 24%, was associated with decreased treatment failure/recurrence, but a previous study associated this allele with increased tuberculosis drug-induced hepatotoxicity [45]. The NR1I2 rs7643645 G allele was associated with treatment failure/recurrence, but a previous report associated this with increased NAFLD severity [44].…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort

Amorim,

Jaworski,

Cordeiro-Santos

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Genetic polymorphisms have been associated with risk of anti-tuberculosis treatment toxicity. We characterized associations with adverse events and treatment failure/recurrence among adults treated for tuberculosis in Brazil. Methods: Participants were followed in Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil. We included persons with culture-confirmed drug-susceptible pulmonary tuberculosis who started treatment between 2015-2019, and who were evaluable for pharmacogenetics. Treatment included 2 months of isoniazid, rifampin or rifabutin, pyrazinamide, and ethambutol, then 4 months of isoniazid and rifampin or rifabutin, with 24 month follow-up. Analyses included 43 polymorphisms in 20 genes related to anti-tuberculosis drug hepatotoxicity or pharmacokinetics. Whole exome sequencing was done in a case-control toxicity subset. Results: Among 903 participants in multivariable genetic association analyses, NAT2 slow acetylator status was associated with increased risk of treatment-related grade 2 or greater adverse events, including hepatotoxicity. Treatment failure/recurrence was more likely among NAT2 rapid acetylators, but not statistically significant at the 5% level. A GSTM1 polymorphism (rs412543) was associated with increased risk of treatment-related adverse events, including hepatotoxicity. SLCO1B1 polymorphisms were associated with increased risk of treatment-related hepatoxicity and treatment failure/recurrence. Polymorphisms in NR1/2 were associated with decreased risk of adverse events and increased risk of failure/recurrence. In whole exome sequencing, hepatotoxicity was associated with a polymorphism in VTI1A, and the genes METTL17 and PRSS57, but none achieved genome-wide significance. Conclusions: In a clinical cohort representing three regions of Brazil, NAT2 acetylator status was associated with risk for treatment-related adverse events. Additional significant polymorphisms merit investigation in larger study populations. Keywords: tuberculosis; pharmacogenetics, drug toxicity, NAT2

show abstract

“…Earlier research studies have validated that multiple lncRNA genetic mutations were linked to the genetic susceptibility towards PTB [ 45 , 46 ]. A recent study found that the level of NEAT1 expression was anomalously high in the peripheral blood mononuclear cells of patients diagnosed with PTB [ 47 ].…”

Section: Roles Of Lncrnas In Tbmentioning

confidence: 99%

Advances of Long Non-Coding RNAs as Potential Biomarkers for Tuberculosis: New Hope for Diagnosis?

Xia

Liu

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Tuberculosis (TB), one of the top ten causes of death globally induced by the infection of Mycobacterium tuberculosis (Mtb), remains a grave public health issue worldwide. With almost one-third of the world’s population getting infected by Mtb, between 5% and 10% of these infected individuals are predicted to develop active TB disease, which would not only result in severe tissue damage and necrosis, but also pose serious threats to human life. However, the exact molecular mechanisms underlying the pathogenesis and immunology of TB remain unclear, which significantly restricts the effective control of TB epidemics. Despite significant advances in current detection technologies and treatments for TB, there are still no appropriate solutions that are suitable for simultaneous, early, rapid, and accurate screening of TB. Various cellular events can perturb the development and progression of TB, which are always associated with several specific molecular signaling events controlled by dysregulated gene expression patterns. Long non-coding RNAs (lncRNAs), a kind of non-coding RNA (ncRNA) with a transcript of more than 200 nucleotides in length in eukaryotic cells, have been found to regulate the expression of protein-coding genes that are involved in some critical signaling events, such as inflammatory, pathological, and immunological responses. Increasing evidence has claimed that lncRNAs might directly influence the susceptibility to TB, as well as the development and progression of TB. Therefore, lncRNAs have been widely expected to serve as promising molecular biomarkers and therapeutic targets for TB. In this review, we summarized the functions of lncRNAs and their regulatory roles in the development and progression of TB. More importantly, we widely discussed the potential of lncRNAs to act as TB biomarkers, which would offer new possibilities in novel diagnostic strategy exploration and benefit the control of the TB epidemic.

show abstract

Correlation between lncRNA AC079767.4 variants and liver injury from antituberculosis treatment in West China

Cited by 4 publications

References 20 publications

Association Between Genetic Polymorphisms of lncRNA NEAT1 and Pulmonary Tuberculosis Risk, Clinical Manifestations in a Chinese Population

Association Between Genetic Polymorphisms of lncRNA NEAT1 and Pulmonary Tuberculosis Risk, Clinical Manifestations in a Chinese Population

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort

Advances of Long Non-Coding RNAs as Potential Biomarkers for Tuberculosis: New Hope for Diagnosis?

Contact Info

Product

Resources

About